Rezolute Inc.
11/06/2025 | Press release | Distributed by Public on 11/06/2025 15:19
Rezolute Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update (Form 8-K)
Rezolute Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update
REDWOOD CITY, Calif., November 6, 2025 - Rezolute, Inc. (Nasdaq: RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today reported financial results and provided a business update for the three months ended September 30, 2025.
"We remain on track to report topline results from the Phase 3 sunRIZE trial in congenital hyperinsulinism in December," said Nevan Charles Elam, Chief Executive Officer and Founder of Rezolute. "In tumor hyperinsulinism, following FDA alignment on our streamlined Phase 3 trial and with enrollment now underway, we expect to both complete enrollment and report topline data in the second half of next year. As we advance toward potential commercialization of ersodetug for the treatment of hyperinsulinism, we look forward to highlighting our progress at our investor event next week."
Recent Pipeline Progress and Anticipated Milestones
Congenital Hyperinsulinism (HI)
| · | sunRIZE, a Phase 3, multicenter, double-blind, randomized, placebo-controlled safety and efficacy study of ersodetug for the treatment of congenital HI, is ongoing. |
| § | Topline results are expected in December 2025. | |
| § | Company has alignment with FDA that the study meets registrational requirements necessary for a BLA filing and review. |
Tumor HI
| · | In August 2025, the Company achieved alignment with FDA on a significantly streamlined clinical development path for its Phase 3 registrational program of ersodetug for the treatment of tumor HI. |
| § | A truncated, single-arm, open-label, Phase 3 study (upLIFT) in up to 16 hospitalized participants is considered acceptable as the adequate and well-controlled study to support registration, removing the need to conduct a double-blind randomized placebo-controlled trial. |
| § | Enrollment is underway and topline results are expected in the second half of 2026. |
Corporate Updates
| · | On November 10, 2025, Rezolute will host a virtual Investor Event via webcast from 12:00-1:30 pm ET. |
| · | During the event, Rezolute Chief Commercial Officer, Sunil Karnawat, will discuss the anticipated commercial opportunities for ersodetug as a potential treatment for congenital and tumor HI. In addition, Rezolute management will review the Company's ongoing clinical development programs, including the Phase 3 sunRIZE and upLIFT trials. |
| · | The call will also feature remarks from two leading physician experts in hyperinsulinism: Mansa Krishnamurthy, M.D., Pediatric Endocrinologist, Cincinnati Children's Hospital Medical Center and Assistant Professor, Department of Pediatrics, University of Cincinnati; and Azeez Farooki, M.D., Attending Physician and Clinical Member, Endocrinology Service, Memorial Sloan Kettering Cancer Center and Associate Clinical Professor, Weill Cornell Medical College. |
First Quarter Fiscal 2026 Financial Results
Cash, cash equivalents and investments in marketable securities were $152.2 million as of September 30, 2025, compared with $167.9 million as of June 30, 2025.
Research and development (R&D) expenses were $13.1 million for the first quarter of fiscal 2026, compared with $12.8 million for the same period a year ago. The increase from fiscal year 2025 to fiscal year 2026 was primarily due to (i) increased expenditures in clinical trial activities and (ii) higher employee-related expenses, which included employee compensation and stock-based compensation, partially offset by a decrease in manufacturing costs for ersodetug.
General and administrative (G&A) expenses were $6.7 million for the first quarter of fiscal 2026, compared with $4.2 million for the same period a year ago. The increase was primarily attributable to professional fees and employee-related expenses due to increased headcount.
Net loss was $18.2 million for the first quarter of fiscal 2026 compared with a net loss of $15.4 million for the same period a year ago.
About Ersodetug
Ersodetug is a fully human monoclonal antibody that binds allosterically to the insulin receptor to decrease receptor over-activation by insulin and related substances (such as IGF-2) in the setting of hyperinsulinism (HI), thereby improving hypoglycemia. Because ersodetug acts downstream from the pancreas, it has the potential to be universally effective at treating hypoglycemia due to any congenital or acquired form of HI.
About Rezolute, Inc.
Rezolute is a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI). The Company's antibody therapy, ersodetug, is designed to treat all forms of HI and has shown meaningful benefit in clinical trials and real-world use for the treatment of both congenital and tumor HI. For more information, visit www.rezolutebio.com.
Rezolute Inc. published this content on November 06, 2025, and is solely responsible for the information contained herein. Distributed via Edgar on November 06, 2025 at 21:25 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]